Hemp Legislation 2026: Federal Bills, State Laws & Industry Impact

Executive Summary

A new congressional hemp bill introduced in May 2026 has ignited fierce opposition from both the alcohol and marijuana industries, marking a pivotal moment in the ongoing regulatory struggle over hemp-derived cannabinoids. The proposed legislation seeks to establish clearer federal guidelines for hemp products, particularly those containing psychoactive compounds like delta-8 THC and THCA, which have proliferated in an ambiguous legal environment since the 2018 Farm Bill. The alcohol industry fears market share erosion from intoxicating hemp beverages, while state-licensed cannabis operators argue that unregulated hemp products undercut their heavily taxed and regulated businesses. This legislative battle represents more than $5 billion in annual hemp product sales and affects thousands of retailers, farmers, and manufacturers operating in the gray area between federal hemp legalization and state cannabis control. The bill's fate will determine whether hemp-derived intoxicating products remain accessible nationwide or face restrictions similar to marijuana, fundamentally reshaping the American cannabinoid marketplace.

Why This Matters

The 2026 hemp legislation debate affects every stakeholder in the $28 billion legal cannabis economy and the rapidly growing hemp sector. For hemp farmers, the outcome determines whether their crops remain viable cash alternatives to traditional agriculture or face new restrictions that could eliminate their most profitable product lines. Over 54,000 licensed hemp acres were cultivated in the United States in 2025, with farmers depending on cannabinoid extraction for economic viability since fiber and seed markets remain underdeveloped. For state-licensed cannabis operators, the stakes are existential. Multi-state operators have invested over $15 billion in licensed facilities that face effective tax rates exceeding 70 percent due to Internal Revenue Code Section 280E, which prohibits standard business deductions for Schedule I substances. These operators watch hemp retailers sell similar intoxicating products with minimal regulation, no excise taxes, and standard business deductions, creating what industry groups call an "unlevel playing field." Consumers face uncertainty about product safety and access. Hemp-derived products currently reach an estimated 15 million Americans through gas stations, convenience stores, and online retailers—distribution channels unavailable to state-licensed cannabis. The FDA has issued warning letters to hemp companies making unsubstantiated health claims but lacks clear regulatory authority over intoxicating hemp cannabinoids. The alcohol industry sees hemp beverages as a direct threat to beer and spirits sales, particularly among younger consumers. Market research indicates that 23 percent of legal-age cannabis consumers reduce alcohol consumption when cannabis products are readily available, according to data from states with mature marijuana markets.

Background and History: From Industrial Fiber to Intoxicating Cannabinoids

The modern hemp regulatory saga began with the Agricultural Act of 2014, which authorized state-regulated pilot programs for industrial hemp research. This legislation, championed by Senate Majority Leader Mitch McConnell of Kentucky, defined hemp as cannabis containing no more than 0.3 percent delta-9 THC on a dry weight basis—a threshold established by Canadian scientist Ernest Small in 1976 for taxonomic purposes, not pharmacological effect.

The 2018 Farm Bill Revolution

The Agriculture Improvement Act of 2018, signed by President Donald Trump on December 20, 2018, removed hemp from the Controlled Substances Act and transferred regulatory authority from the DEA to the United States Department of Agriculture. Section 10113 of the Farm Bill explicitly legalized hemp and hemp-derived products, creating what advocates celebrated as the end of decades of prohibition. The legislation defined hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition, codified at 7 U.S.C. § 1639o, contained no restrictions on other cannabinoids, creating a legal framework that entrepreneurs would exploit.

The Delta-8 THC Explosion (2019-2021)

In 2019, chemists discovered they could convert CBD extracted from legal hemp into delta-8 THC through chemical synthesis. Delta-8 THC, a naturally occurring cannabinoid found in trace amounts in cannabis, produces intoxicating effects similar to delta-9 THC but remained technically legal under the Farm Bill's language. By 2020, delta-8 products flooded gas stations, smoke shops, and online retailers. The DEA issued an Interim Final Rule on August 21, 2020, stating that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances," but the agency's authority over hemp-derived substances remained contested. Hemp industry attorneys argued that the Farm Bill's removal of hemp from the CSA superseded DEA scheduling authority for hemp derivatives.

State Responses and Fragmentation (2021-2023)

States responded inconsistently to intoxicating hemp products. By December 2023, fourteen states had explicitly banned delta-8 THC and similar hemp-derived intoxicants, including Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Mississippi, Montana, New York, North Dakota, Rhode Island, Utah, and Vermont. Another dozen states implemented age restrictions and labeling requirements without outright bans. Colorado's ban proved particularly significant because the state's licensed marijuana industry lobbied aggressively for hemp restrictions. The Colorado Department of Public Health and Environment classified delta-8 THC as a Schedule I controlled substance in October 2021, arguing that chemically converted cannabinoids fell outside the Farm Bill's protections.

THCA: The Latest Loophole (2023-2025)

As states restricted delta-8 THC, hemp entrepreneurs pivoted to THCA—tetrahydrocannabinolic acid, the non-intoxicating precursor to delta-9 THC found naturally in cannabis plants. When heated through smoking or vaping, THCA converts to delta-9 THC through decarboxylation, producing identical effects to marijuana. Because the Farm Bill measures only delta-9 THC content in unheated plant material, THCA flower containing less than 0.3 percent delta-9 THC but high levels of THCA (often 15-25 percent) remained technically legal. By 2024, THCA flower had become the fastest-growing segment of the hemp market, with sales exceeding $2 billion annually. Retailers marketed THCA products as "legal weed" available for shipping to most states, creating alarm among both regulators and licensed cannabis operators.

The FDA's Struggle for Authority (2019-2026)

The Food and Drug Administration found itself in regulatory limbo after the 2018 Farm Bill. The agency maintained that CBD and other cannabinoids required FDA approval before being added to food, beverages, or dietary supplements under the Federal Food, Drug, and Cosmetic Act. However, the FDA lacked enforcement resources to police thousands of hemp retailers and issued only sporadic warning letters. In July 2023, the FDA requested public comment on a regulatory framework for CBD products, receiving over 12,000 submissions. As of May 2026, the agency has not issued final regulations, leaving hemp businesses operating without clear federal food and drug safety standards.

Key Players in the 2026 Legislative Battle

Congressional Sponsors and Hemp Advocates

The 2026 hemp bill, formally titled the Hemp Advancement Act of 2026, was introduced in the House by Representative James Comer of Kentucky and in the Senate by Majority Leader Mitch McConnell. Both legislators represent Kentucky, where hemp cultivation has become a significant agricultural sector with over 8,000 licensed acres in 2025. The U.S. Hemp Roundtable, an industry coalition representing farmers, processors, and retailers, has lobbied extensively for the legislation. The organization argues that clear federal standards will protect consumers while preserving market access for compliant hemp businesses. Executive Director Jonathan Miller has emphasized that the bill includes age restrictions, testing requirements, and serving size limits for intoxicating hemp products.

The Cannabis Industry Opposition

The National Cannabis Industry Association and the Cannabis Trade Federation have mobilized against the hemp bill, arguing it would legitimize unregulated intoxicating products that compete directly with state-licensed marijuana. Aaron Smith, co-founder of the National Cannabis Industry Association, has stated that hemp-derived intoxicants should face the same regulatory scrutiny as marijuana, including laboratory testing, child-resistant packaging, and excise taxation. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have funded lobbying efforts against the legislation. These companies argue that they have invested billions in compliance infrastructure while hemp competitors operate with minimal oversight. The licensed industry points to laboratory testing data showing that many hemp products contain inaccurate cannabinoid labeling and contaminants including heavy metals and pesticides.

The Alcohol Industry's Concerns

The Distilled Spirits Council of the United States and the Beer Institute have opposed provisions in the hemp bill that would explicitly authorize intoxicating hemp beverages. Industry representatives argue that hemp drinks should face the same federal oversight as alcoholic beverages, including production facility inspections and distribution controls through the three-tier system. Market data has heightened alcohol industry concerns. Nielsen reported that beer sales declined 2.3 percent in states with legal marijuana dispensaries between 2022 and 2025, compared to 0.8 percent declines in prohibition states. Hemp beverage sales, though still small at approximately $400 million annually, grew 180 percent in 2025.

Federal Agencies: USDA, DEA, and FDA

The United States Department of Agriculture has maintained a neutral public position on the legislation while privately expressing concerns about enforcement capacity. The USDA's hemp program focuses on THC testing of crops pre-harvest but has no authority over post-harvest processing or finished products. The Drug Enforcement Administration has argued that chemically converted cannabinoids fall under its scheduling authority regardless of their hemp origin. DEA Administrator Anne Milgram testified before Congress in March 2026 that delta-8 THC and similar substances meet the definition of "synthetic" controlled substances under 21 U.S.C. § 802(6). However, the agency has conducted minimal enforcement against hemp retailers, focusing resources on fentanyl and methamphetamine trafficking. The FDA has requested explicit statutory authority over hemp-derived cannabinoid products in food and beverages, which the current bill would provide. The agency has emphasized that without clear authority, it cannot establish serving size limits, labeling standards, or good manufacturing practice requirements for hemp products.

Legal and Regulatory Framework

The 2026 hemp legislation operates within a complex federal statutory framework spanning agricultural law, controlled substances regulation, and food and drug safety. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes five schedules of controlled substances based on abuse potential and medical utility. Marijuana remains a Schedule I substance alongside heroin and LSD, defined as having no accepted medical use and high abuse potential. The 2018 Farm Bill created an exception for hemp by amending the CSA's definition of marijuana to exclude cannabis containing 0.3 percent or less delta-9 THC. This exception appears in 21 U.S.C. § 802(16), which now defines marijuana as "all parts of the plant Cannabis sativa L., whether growing or not... except... the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination, and... hemp, as defined in section 1639o of title 7." The statutory definition creates ambiguity about chemically converted cannabinoids and naturally occurring isomers of THC. Courts have not definitively ruled whether delta-8 THC synthesized from CBD falls within the Farm Bill's hemp exception or constitutes a "synthetic" controlled substance under DEA authority. The Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., requires FDA approval before adding drug ingredients to food or marketing substances as dietary supplements. The FDA has maintained that CBD and other cannabinoids are excluded from the dietary supplement definition under 21 U.S.C. § 321(ff)(3)(B) because they were investigated as drugs before being marketed as supplements. This interpretation would prohibit hemp cannabinoids in supplements and foods without FDA approval, but the agency has not enforced this position consistently. The 2026 Hemp Advancement Act would amend 7 U.S.C. § 1639o to establish explicit standards for intoxicating hemp products, including:

• Maximum serving sizes of 10 milligrams of "total THC" (including THCA and delta-8 THC) per serving
• Maximum package sizes of 100 milligrams total THC
• Mandatory laboratory testing for potency and contaminants
• Child-resistant packaging requirements
• Minimum age of 21 for purchase
• FDA authority to establish good manufacturing practices

The bill would also amend the CSA to clarify that all hemp-derived cannabinoids meeting the 0.3 percent delta-9 THC threshold remain non-controlled substances, regardless of intoxicating effects or synthesis methods.

State-by-State Breakdown

State approaches to hemp-derived intoxicants vary dramatically, creating a patchwork regulatory landscape that the 2026 federal legislation seeks to harmonize.

Prohibition States

Fourteen states have banned delta-8 THC and similar intoxicating hemp derivatives: Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Mississippi, Montana, New York, North Dakota, Rhode Island, Utah, and Vermont. These states typically classify chemically converted cannabinoids as controlled substances under state law, regardless of federal hemp status. Colorado's approach has been most aggressive, with the state classifying any "chemically modified or converted" cannabinoid as a controlled substance. The Colorado Department of Revenue requires all intoxicating cannabinoid products to be sold exclusively through licensed marijuana dispensaries, subject to the state's 15 percent retail marijuana excise tax.

Regulated-but-Legal States

Twenty-three states allow hemp-derived intoxicants with varying restrictions. Minnesota established a comprehensive regulatory framework in 2023, requiring hemp beverage manufacturers to obtain licenses, limiting serving sizes to 5 milligrams THC for beverages and 50 milligrams per package, and imposing a 10 percent excise tax. The Minnesota model has been studied by other states as a middle-ground approach. California permits hemp-derived cannabinoids but requires compliance with the state's Proposition 65 warning label system for products containing detectable THC. The California Department of Public Health has issued guidance that hemp products containing more than 0.5 milligrams THC per serving must carry cancer and reproductive harm warnings, though scientific evidence for such warnings remains contested. Texas allows hemp products under the state's hemp program administered by the Texas Department of State Health Services, but local prosecutors have charged retailers with marijuana distribution in some jurisdictions, creating legal uncertainty. The Texas Hemp Federation has reported over 200 enforcement actions against hemp retailers since 2023, though most charges were eventually dismissed.

Unregulated States

Thirteen states have neither banned nor specifically regulated intoxicating hemp products, leaving retailers operating under the 2018 Farm Bill's federal framework alone. These states include Alabama, Georgia, Indiana, Kansas, Louisiana, Missouri, Nebraska, New Mexico, Oklahoma, South Carolina, Tennessee, West Virginia, and Wyoming. Florida represents a unique case, where the state's hemp program allows intoxicating products but the Department of Agriculture has issued conflicting guidance. Florida's hemp market exceeded $800 million in sales in 2025, making it the largest hemp product market in the Southeast.

States with Adult-Use Marijuana Programs

States with legal recreational marijuana face particular tension between hemp and cannabis regulations. Oregon requires hemp retailers to obtain marijuana retailer licenses to sell any intoxicating product, effectively eliminating the regulatory distinction. Washington State has proposed similar requirements but has not yet implemented them. Michigan allows hemp products to be sold separately from marijuana dispensaries but requires compliance with the state's marijuana testing standards, including limits on pesticides, heavy metals, and microbial contaminants. This approach creates higher compliance costs for hemp retailers but maintains separate licensing pathways.

Market and Business Implications

The hemp legislation debate occurs against a backdrop of rapid market growth and significant capital investment across both hemp and licensed cannabis sectors. The hemp-derived cannabinoid market reached $5.2 billion in retail sales in 2025, according to data from the Hemp Industry Association. This figure includes CBD products ($3.1 billion), delta-8 THC and similar intoxicants ($1.8 billion), and minor cannabinoids like CBG and CBN ($300 million). Growth rates have exceeded 40 percent annually since 2022, driven primarily by intoxicating product sales. Multi-state operators in the licensed cannabis sector reported combined revenue of $23 billion in 2025, but profitability remains elusive for most companies due to 280E taxation and price compression in mature markets. Wholesale cannabis prices declined 35 percent between 2023 and 2025 in California, forcing cultivators to abandon over 40 percent of licensed acreage. The alcohol industry's opposition reflects genuine market share concerns. Hemp beverage sales grew from $140 million in 2023 to $400 million in 2025, with projections reaching $1.2 billion by 2028 if current regulations remain unchanged. Constellation Brands, which owns Corona and Modelo beer brands, invested $4 billion in Canadian cannabis company Canopy Growth in 2018 but has since written down most of that investment's value, making the company particularly sensitive to hemp competition. Investment capital has flowed heavily into hemp businesses operating in the regulatory gray area. Private equity firms invested over $800 million in hemp companies in 2024 and 2025, attracted by the sector's ability to operate across state lines and access traditional banking services unavailable to marijuana businesses. Hemp companies can list on major stock exchanges, accept credit card payments, and deduct business expenses—advantages that create 40-60 percent cost structure advantages over licensed cannabis operators. Retail distribution represents the most significant market difference. Hemp products reach consumers through approximately 80,000 retail locations nationwide, including convenience stores, gas stations, tobacco shops, and online retailers. Licensed marijuana dispensaries number only about 15,000 locations and cannot ship products across state lines. This distribution advantage allows hemp brands to achieve national scale impossible for cannabis companies. The proposed legislation would likely consolidate the hemp market by imposing compliance costs that favor larger operators. Mandatory laboratory testing, child-resistant packaging, and good manufacturing practice requirements could add $0.50 to $2.00 per unit in costs, making low-price gas station products economically unviable. Industry analysts project that 40-60 percent of current hemp retailers would exit the market if the legislation passes with its current compliance requirements.

What Experts Say

Legal scholars, medical professionals, and industry analysts have offered sharply divergent views on the appropriate regulatory framework for hemp-derived intoxicants. Professor Robert Mikos of Vanderbilt Law School, a leading expert on cannabis federalism, has argued that the 2018 Farm Bill's language clearly encompasses all hemp derivatives regardless of intoxicating effects. According to Mikos, Congress could have limited the hemp exception to non-intoxicating products but chose not to, making current hemp products legally defensible under federal law even if they produce effects similar to marijuana. Dr. Yasmin Hurd, director of the Addiction Institute at Mount Sinai, has expressed concern about the lack of research on delta-8 THC and other hemp-derived cannabinoids. Hurd notes that while delta-9 THC has been studied extensively, the safety profiles of chemically converted cannabinoids remain largely unknown. She has called for FDA oversight and mandatory adverse event reporting before these products gain wider distribution. Jonathan Miller of the U.S. Hemp Roundtable has emphasized that responsible hemp businesses support reasonable regulations including age restrictions, testing requirements, and serving size limits. Miller argues that the 2026 legislation would eliminate bad actors while preserving market access for compliant companies, ultimately benefiting consumers through improved product safety. Aaron Smith of the National Cannabis Industry Association has countered that any regulatory framework legitimizing intoxicating hemp products undermines state marijuana programs that voters approved through ballot initiatives. Smith contends that if Congress wants to legalize intoxicating cannabis products nationwide, it should do so explicitly through marijuana descheduling rather than through agricultural hemp policy. Dr. Peter Grinspoon, a cannabis specialist at Massachusetts General Hospital, has noted that from a medical perspective, the distinction between hemp-derived and marijuana-derived THC is meaningless—the molecule is identical regardless of source. Grinspoon has argued that regulatory frameworks should focus on product safety, accurate labeling, and preventing youth access rather than the plant source of cannabinoids. Economists at the Marijuana Policy Group, a Colorado-based research firm, have analyzed the market impact of hemp competition on licensed cannabis businesses. Their research indicates that states with unrestricted hemp sales see 15-20 percent lower marijuana tax revenue than projected, suggesting significant market substitution. However, they note that total cannabinoid consumption increases when hemp products are available, indicating market expansion rather than pure substitution.

What's Next: Legislative Timeline and Scenarios

The Hemp Advancement Act of 2026 faces a complex legislative path with multiple decision points over the next twelve months. The House Agriculture Committee scheduled hearings on the bill for June 2026, with testimony expected from the USDA, FDA, DEA, hemp industry representatives, cannabis industry groups, and public health organizations. Committee Chairman Glenn Thompson of Pennsylvania has indicated openness to amendments that address concerns from both the cannabis and alcohol industries, suggesting the bill will evolve significantly before any floor vote. In the Senate, the bill must pass through the Agriculture, Nutrition, and Forestry Committee, where Chairman John Boozman of Arkansas has expressed skepticism about legitimizing intoxicating hemp products. Arkansas banned delta-8 THC in 2021, and Boozman has stated that hemp should remain focused on fiber, seed, and non-intoxicating CBD applications. This opposition from the committee chairman could delay or derail Senate consideration. The legislative calendar presents challenges for passage in 2026. Congress faces a September 30 deadline for appropriations bills to avoid a government shutdown, and the November 2026 midterm elections will consume legislative attention in the fall. Realistically, the hemp bill would need to pass both chambers by August 2026 to reach the President's desk this year. Several scenarios could unfold: Scenario 1: Compromise Legislation — The most likely outcome involves amendments that tighten restrictions on intoxicating hemp products while preserving some market access. This could include lower serving size limits (5 milligrams instead of 10 milligrams), state opt-out provisions allowing states to ban products regardless of federal law, and excise taxes that partially level the playing field with marijuana. Such a compromise might gain support from moderate legislators in both parties. Scenario 2: Attachment to Farm Bill — Hemp provisions could be incorporated into the broader 2027 Farm Bill reauthorization, which must pass by September 30, 2027. This approach would give legislators more time to negotiate compromises and would make the hemp provisions part of a must-pass legislative package. However, it would also delay resolution of the regulatory uncertainty by at least sixteen months. Scenario 3: Regulatory Action Without Legislation — If Congress fails to act, the DEA could issue a final rule clarifying that chemically converted cannabinoids are controlled substances, effectively banning delta-8 THC and similar products without legislation. The FDA could simultaneously issue guidance asserting jurisdiction over hemp products in food and beverages. This regulatory approach would face legal challenges but could reshape the market faster than legislation. Scenario 4: Status Quo Continuation — The bill could fail entirely, leaving the current patchwork of state regulations in place. This outcome would benefit hemp businesses operating in permissive states but would perpetuate regulatory uncertainty and consumer safety concerns. Industry observers are also watching for potential marijuana rescheduling developments that could affect the hemp debate. The DEA's proposed rule to reschedule marijuana from Schedule I to Schedule III remains pending as of May 2026, with a final decision expected by late 2026 or early 2027. If marijuana moves to Schedule III, it would remain federally controlled but would allow licensed businesses to deduct ordinary business expenses, partially addressing the 280E tax disadvantage that makes hemp competition particularly painful for cannabis operators.

Further Reading and Primary Sources

• Agriculture Improvement Act of 2018, Public Law 115-334, 132 Stat. 4490 (December 20, 2018) — Full text of the Farm Bill that legalized hemp: https://www.congress.gov/bill/115th-congress/house-bill/2
• 7 U.S.C. § 1639o — Federal statutory definition of hemp and USDA regulatory framework: https://www.law.cornell.edu/uscode/text/7/1639o
• 21 U.S.C. § 802(16) — Controlled Substances Act definition of marijuana with hemp exception: https://www.law.cornell.edu/uscode/text/21/802
• DEA Interim Final Rule, "Implementation of the Agriculture Improvement Act of 2018," 85 Fed. Reg. 51639 (August 21, 2020) — DEA position on synthetically derived cannabinoids: https://www.federalregister.gov/documents/2020/08/21/2020-18564/implementation-of-the-agriculture-improvement-act-of-2018
• USDA Hemp Production Program, 7 CFR Part 990 — Federal regulations for hemp cultivation and testing: https://www.ams.usda.gov/rules-regulations/hemp
• FDA Regulation of Cannabis and Cannabis-Derived Products — Agency position on CBD and hemp products: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
• U.S. Hemp Roundtable Policy Positions — Industry coalition advocacy materials: https://www.hempsupporter.com
• National Cannabis Industry Association Policy Statements — Licensed cannabis industry perspective: https://thecannabisindustry.org
• Congressional Research Service, "The 2018 Farm Bill and Hemp Production," R46186 (updated regularly) — Nonpartisan analysis of hemp legal framework: https://crsreports.congress.gov
• Marijuana Policy Group, "Economic Impact of Hemp-Derived Cannabinoids on State Cannabis Markets" (2025) — Market analysis and revenue impacts: https://www.mjpolicygroup.com